Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
22/04/2024 13:23
April 22 (Reuters) - Endo International PLC ENDPQ.PK :
* PAR PHARMACEUTICAL ISSUES VOLUNTARY NATIONWIDE RECALL OF
SEVEN
LOTS OF TREPROSTINIL INJECTION DUE TO POTENTIAL FOR SILICONE
PARTICULATES IN THE PRODUCT SOLUTION
* ENDO INTERNATIONAL- PAR PHARMACEUTICAL EXPANDING
VOLUNTARY
RECALL TO INCLUDE 7 LOTS OF TREPROSTINIL INJECTION 20MG/20ML
(1MG/ML) TO CONSUMER LEVEL
Source text for Eikon: ID:nPn53GC2ba
Further company coverage: ENDPQ.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes